Aspect Biosystems is proud to announce a collaboration with Merck, GSK, and McGill University’s Goodman Cancer Research Centre. This $2.2M project is made possible by contributions from CQDM, the Canadian Cancer Society, Merck, GSK, Aspect Biosystems, and McGill University. These contributions underscore their commitment to driving innovation that will unlock the discovery of novel therapeutic targets and the development of…
Read More
A team of scientists partly funded by the Terry Fox Research Institute has shown that nearly half of all patients with peritoneal mesothelioma (PeM), an extremely rare and often fatal form of cancer that originates in the peritoneal lining of the abdomen, may benefit from immunotherapy. Their work, published in Genome Medicine (February 2019), is being heralded as a breakthrough by some…
Read More
Autism spectrum disorder (ASD) is a mental disorder affecting the development of the nervous system, characterized by deficits in social communication and repetitive behaviours. This condition manifests in early childhood and lasts a person’s entire lifetime, and the most important risk factor is genetic. The genetics of ASD is very complex and involves an interplay between common inherited DNA variants…
Read More
Microglia are the brain’s immune cells, and they work together to maintain brain health and remove “junk” that builds up in brain tissue. They are the brain’s tiny helper cells, and changes in their appearance can indicate degeneration or disease in surrounding cells and tissue. In the past, microglia were thought to be inactive unless called upon by threat or…
Read More
Zymeworks is playing a fundamental role is ensuring Vancouver becomes a global centre of excellence in biotech Defeating cancer is an audacious goal, but that’s exactly what the team at Vancouver-based Zymeworks hopes to do. The biotech company has developed protein therapeutics for the treatment of cancer and for autoimmune and inflammatory diseases. They’re also developing a new delivery system and…
Read More
Two successful Canadian innovation organizations, CDRD, Canada’s national life sciences venture, and NEOMED Institute, a leading not-for-profit R&D organization building an innovation ecosystem in Montréal, are pleased to announce that effective today, they are bringing their respective capabilities and resources together under a new co-founded pan-Canadian enterprise, adMare BioInnovations. Working from sea to sea, and reaching globally, adMare is focused…
Read More
The University of British Columbia has reaffirmed its strong commitment to enhancing equity, diversity and inclusion in research by endorsing the Government of Canada’s Dimensions charter. Dimensions: Equity, Diversity and Inclusion Canada is a pilot program that aims to address systemic barriers, particularly those experienced by members of underrepresented or disadvantaged groups. Institutions that endorse the Dimensions charter, unveiled earlier this month…
Read More

New Approaches to Study the Genetics of Autism Spectrum Disorder May Lead to New Therapies

Canadian neuroscientists are using novel experimental approaches to understand autism spectrum disorder, from studying multiple variation in a single gene to the investigation of networks of interacting genes to find new treatments for the disorder. Autism spectrum disorder (ASD) affects more than 1% of children, yet most cases are of unknown or poorly defined genetic origin. It is highly variable…
Read More

Walking the Tightrope

Imagine, you are walking on a tightrope. If you fall to one side of this narrow line, zombies are waiting to eat you up. On the other side, it is a fall into a crazy deep canyon. Terrifying, isn’t it? However, there is good news! By having the prefect concert of one’s movement, balance and coordination, tightrope can be mastered.…
Read More
Our paper was driven by BC Cancer’s efforts toward precision oncology in British Columbia. Precision oncology uses DNA and RNA sequencing to find molecular anomalies that may be the driving force behind a cancer. At BC Cancer, we use this information to guide treatment decisions as part of our Personalized OncoGenomics (POG) program. However, it’s one thing to have sequence information from a tumour…
Read More